Bernier FP, Snyder FF, McLeod DR: Deficiency of 5-oxoprolinase in an 8-year-old with developmental delay
Regional Outlook and Growth Opportunities The market demonstrates strong regional growth dynamics: USA (18.2% CAGR): Leading adoption driven by GLP-1 therapy penetration and product innovation UK (16.4% CAGR): Growth through DTC nutrition brands and functional meal formats Germany (15.8% CAGR): High demand for premium, structured nutrition solutions Japan (15.1% CAGR): Convenience-led, portion-controlled innovation South Korea (14.7% CAGR): Growth in functional beverages and snack formats North America leads commercialization, while Europe and East Asia drive premiumization and format innovation
Glutathione treatment improved CAP values in ALT responders The median decrease in ALT level from baseline was 12.9%
doi: 10.1093/ajcn/84.1.88 145 JiangXBarHYYanJWestAAPerryCAMalyshevaOVet al
Recent large-scale clinical trials have been conducted to verify the weight loss effects of GLP-1RAs, especially liraglutide and semaglutide, in patients without diabetes [12, 13], which showed statistically significant weight loss when compared with lifestyle modification only
Broader Endothelial Pathway Coverage Klow integrates peptides that modulate nitric oxide synthesis, regulate cytoskeletal remodeling, and promote angiogenic gene expression